Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Vγ9Vδ2 T cells play a major role in cancer immunosurveillance and when activated — using activating antibodies to butyrophilin 3A (BTN3A) — can eliminate diverse tumour cell types in vitro and in vivo. Now, De Gassart et al. report a humanized anti-BTN3A, Vγ9Vδ2 T cell–activating, monoclonal antibody with potent cytotoxic activity in human cancer cell lines. ICT01 delayed tumour growth and prolonged survival in tumour xenograft mouse models and safely induced Vγ9Vδ2 T cell activation and trafficking in monkeys. In a phase I/IIa study in patients with solid tumours, preliminary results indicate that ICT01 is well tolerated and pharmacodynamically active.
Prices may be subject to local taxes which are calculated during checkout
Nature Reviews Drug Discovery20, 898 (2021)
doi: https://doi.org/10.1038/d41573-021-00185-6
References
De Gassart, A. et al. Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell–mediated antitumor immune response. Sci. Transl Med.13, eabj0835 (2021)
